董事會會議召開日期 杭州泰格醫藥科技股份有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣 佈，董事會會議將於二零二三年八月二十五日（星期五）舉行，藉以（其中包括）審 議及批准本公司及其附屬公司截至二零二三年六月三十日止六個月的未經審核中 期業績及其刊發，以及考慮宣派及派付中期股息（如適用）。 承董事會命 杭州泰格醫藥科技股份有限公司 葉小平 董事長 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭州泰格醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3347) 香港，二零二三年八月十五日 於本公告日期，執行董事為葉小平博士、曹曉春女士、吳灝先生及聞增玉先生； 獨立非執行董事為楊波博士、廖啟宇先生及袁華剛先生。 ...

创业板投资风险提示 本次发行股票拟在创业板上市，创业板公司具有创新投入大、新旧产业融合存在 不确定性、尚处于成长期、经营风险高、业绩不稳定、退市风险高等特点，投资者面 临较大的市场风险。投资者应充分了解创业板的投资风险及本公司所披露的风险因 素，审慎作出投资决定。 安徽万邦医药科技股份有限公司 Anhui Wanbang Pharmaceutical Technology Co., Ltd. （安徽省合肥市高新区明珠大道与火龙地路交口西南角安徽万邦医药 1 号楼） 首次公开发行股票并在创业板上市 招股说明书 （注册稿） 公司的发行申请尚需经深圳证券交易所和中国证监会履行相应程序。本 招股说明书（注册稿）不具有据以发行股票的法律效力，仅供预先披露之 用。投资者应当以正式公告的招股说明书全文作为投资决定的依据。 保荐机构（主承销商） （中国（上海）自由贸易试验区浦明路 8 号） 安徽万邦医药科技股份有限公司 招股说明书（注册稿） 声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发 行人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表 明其对发行人的盈利能力、投资价值或者对投资者 ...

Financial Performance - In 2022, the company's revenue increased by 35.9% year-on-year, reaching RMB 7,085.5 million, up from RMB 5,213.5 million in 2021[5]. - Gross profit for 2022 was RMB 2,785.4 million, up 23.9% from RMB 2,248.1 million in 2021[12]. - Net profit attributable to the company's owners decreased by 30.0% to RMB 2,016.1 million from RMB 2,879.1 million in 2021[12]. - Revenue for the year ended December 31, 2022, was RMB 7,085.5 million, representing a 35.9% increase from RMB 5,213.5 million in 2021[12]. - The company secured new orders amounting to RMB 9,673.4 million in 2022, slightly up from RMB 9,645.5 million in the previous year[18]. - The future contracted revenue as of December 31, 2022, was RMB 13,785.9 million, reflecting a year-on-year increase of 20.9%[19]. - The adjusted net profit attributable to the company's owners decreased by 30.0% year-on-year to RMB 2,016.1 million, compared to RMB 2,879.1 million in the same period last year[64]. - The net profit for the year decreased by 32.8% year-on-year to RMB 2,281.3 million, down from RMB 3,396.6 million in the same period last year[64]. Revenue Breakdown - Revenue from clinical trial technical services amounted to RMB 4,125.2 million, while revenue from clinical trial-related services and laboratory services reached RMB 2,960.3 million, reflecting year-on-year growth of 37.8% and 33.4% respectively[5]. - Revenue generated in China grew by 30.7% year-on-year to RMB 3,601.6 million, while overseas revenue increased by 41.8% to RMB 3,483.9 million[5]. - Revenue from clinical trial-related services and laboratory services increased by 33.4% year-on-year to RMB 2,960.3 million, up from RMB 2,219.9 million in the same period last year[41]. Project and Service Expansion - The number of ongoing drug clinical research projects increased from 567 as of December 31, 2021, to 680 as of December 31, 2022[6]. - The company signed 21 new multi-regional clinical trial projects during the reporting period, increasing ongoing multi-regional clinical trials from 50 to 62[8]. - The number of ongoing single-region clinical trials rose from 132 to 188, while multi-region trials increased from 50 to 62 during the same period[22]. - The company established 189 clinical trial excellence centers and 100 green channel centers in China by December 31, 2022[8]. - The company expanded its global presence by establishing new subsidiaries in the UK, Netherlands, and Argentina, totaling 29 subsidiaries across five continents[20]. Investment and Acquisitions - The company completed the acquisition of European contract research organization Marti Farm D.o.o. in January 2023, enhancing local regulatory expertise in Europe[8]. - The company completed the acquisition of Experimur LLC for a total cash consideration of up to $76 million, which has been integrated into the company's consolidated financial statements[106]. - The company acquired 100% of Meditip Co., Ltd for a cash consideration of 20,091,556,000 KRW (approximately RMB 105.4 million), enhancing its market research capabilities in the biopharmaceutical sector[110]. - The company approved the acquisition of 88.1% of Frontage Clinical for approximately $13.215 million, which will be consolidated into the company's financial statements[118]. Workforce and Talent Management - The number of employees increased from 8,326 to 9,233, reflecting a growth in workforce[26]. - The company has recruited over 560 interns for clinical trial-related positions during the reporting period, collaborating with over 23 universities to attract high-quality graduates[101]. - The company has implemented a competitive compensation package, including long-term equity incentive plans, to enhance its competitive advantage and talent retention[102]. - The company faces a risk of talent loss, as the competition for qualified personnel is intense, which could significantly impact its competitiveness and financial performance[150]. Corporate Governance - The board consists of seven members, including four executive directors and three independent non-executive directors[157]. - The company emphasizes the importance of independent directors in ensuring corporate governance and strategic oversight[165]. - The company has adopted corporate governance practices in line with the principles outlined in the listing rules, maintaining high standards of governance throughout the reporting period[177]. - The audit committee, composed of three independent non-executive directors, held three meetings during the reporting period to review financial performance and internal controls[199]. Market Trends and Challenges - The global contract research organization (CRO) market size increased from $52.54 billion in 2017 to $75.94 billion in 2021, with a compound annual growth rate (CAGR) of 9.7%[123]. - The company anticipates continued business development and expansion, necessitating significant management, financial, and human resources to enhance services and technology[142]. - Increased competition in the global pharmaceutical contract research market may lead to pricing pressure, potentially reducing revenue and profitability[140]. - The regulatory environment in China is increasingly stringent, driving demand for emerging business services related to drug lifecycle management[131]. Strategic Goals and Future Outlook - The company aims to create lasting value for all stakeholders despite global macroeconomic challenges and the impact of the pandemic[5]. - The company plans to continue increasing R&D investment in response to growing market demand for innovative drugs and medical devices[123]. - The company aims to optimize services to meet the evolving needs of clients, supported by its growing and diversified customer base[103]. - The company is committed to investing in innovative biopharmaceutical and medical device startups, aiming to build long-term partnerships and promote industry innovation[104].

Financial Performance - Revenue for Q1 2023 was RMB 1,804.57 million, a slight decrease of 0.73% compared to the same period last year[3] - Net profit attributable to shareholders increased by 9.65% to RMB 568.46 million in Q1 2023[3] - Total revenue for the first quarter of 2023 was 1,804,571,375.28 RMB, a slight decrease from 1,817,858,958.69 RMB in the same period last year[16] - Operating profit for the first quarter of 2023 was 630,897,782.90 RMB, compared to 654,381,329.25 RMB in the same period last year[17] - Net profit for the first quarter of 2023 was 568,325,660.27 RMB, slightly down from 573,970,498.59 RMB in the same period last year[17] - Net profit attributable to parent company owners increased to 568.46 million yuan, up 9.66% from 518.42 million yuan in the previous period[18] - Comprehensive income totaled 521.77 million yuan, down 8.69% from 571.45 million yuan in the previous period[18] - Basic earnings per share increased to 0.66 yuan, up 10% from 0.60 yuan in the previous period[18] - Revenue from sales of goods and services decreased to 1.53 billion yuan, down 13.16% from 1.76 billion yuan in the previous period[19] Cash Flow - Operating cash flow decreased significantly by 90.59% to RMB 28.51 million due to reduced large project payments and increased operating expenses[9] - Investment cash flow improved by 57.74% to a net outflow of RMB 547.51 million, as there were no significant acquisition payments compared to the previous year[9] - Cash flow from operating activities decreased to 28.51 million yuan, down 90.59% from 303.08 million yuan in the previous period[20] - Cash flow from investing activities improved to -547.51 million yuan, compared to -1.30 billion yuan in the previous period[20] - Cash flow from financing activities decreased to 302.16 million yuan, down 43.34% from 533.08 million yuan in the previous period[20] - Cash and cash equivalents at the end of the period stood at 7.55 billion yuan, down 4.59% from 7.92 billion yuan in the previous period[21] - Cash paid for employee compensation increased to 788.73 million yuan, up 16.37% from 677.79 million yuan in the previous period[20] - Cash received from tax refunds increased to 3.13 million yuan, up 427.47% from 593,915.44 yuan in the previous period[20] Assets and Liabilities - The company's total assets grew by 2.64% to RMB 28.17 billion as of the end of Q1 2023[3] - Total assets at the end of the period amount to 28,172,127,699.99 yuan[14] - Total liabilities for the first quarter of 2023 were 4,853,582,844.27 RMB, compared to 4,765,479,654.95 RMB in the same period last year[15] - Total equity for the first quarter of 2023 was 23,318,544,855.72 RMB, up from 22,681,030,941.49 RMB in the same period last year[15] - Contract liabilities for the first quarter of 2023 were 870,900,929.39 RMB, down from 911,073,826.39 RMB in the same period last year[15] - Employee compensation payable for the first quarter of 2023 was 170,191,493.18 RMB, down from 292,868,161.24 RMB in the same period last year[15] - Taxes payable for the first quarter of 2023 were 180,537,915.05 RMB, down from 197,737,378.83 RMB in the same period last year[15] - Long-term loans for the first quarter of 2023 were 280,710,389.80 RMB, up from 244,641,137.61 RMB in the same period last year[15] - Lease liabilities for the first quarter of 2023 were 466,590,632.04 RMB, down from 488,975,554.75 RMB in the same period last year[15] - Monetary funds at the end of the period amount to 7,616,130,648.84 yuan[14] - Accounts receivable at the end of the period amount to 1,077,375,173.77 yuan[14] Shareholder Information - Total number of ordinary shareholders at the end of the reporting period is 40,921[10] - Ye Xiaoping holds 20.32% of the shares, totaling 177,239,541 shares[10] - HKSCC NOMINEES LIMITED holds 14.11% of the shares, totaling 123,119,379 shares[10] - Hong Kong Securities Clearing Company Limited holds 9.26% of the shares, totaling 80,821,415 shares[10] - Cao Xiaochun holds 5.92% of the shares, totaling 51,661,774 shares[10] - Industrial and Commercial Bank of China - China Europe Medical Health Hybrid Securities Investment Fund holds 4.20% of the shares, totaling 36,652,574 shares[10] - TEMASEK FULLERTON ALPHA PTE LTD holds 2.23% of the shares, totaling 19,469,370 shares[10] Clinical Trial Services - Clinical trial technical service revenue declined slightly due to a reduction in multi-regional clinical trial business, particularly vaccine-related trials[6] - Clinical trial-related services and laboratory service revenue increased, driven by growth in data management, statistical analysis, and patient recruitment services[6] Financial Metrics - Fair value change gains increased by 40.98% to RMB 176.41 million, mainly due to gains from other non-current financial assets[8] - Financial expenses decreased by 47.37% to RMB -15.96 million, primarily due to reduced interest expenses[8] - The company's weighted average return on equity (ROE) slightly increased by 0.03 percentage points to 2.86%[3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭 州 泰 格 醫 藥 科 技 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3347） 2023年第一季度報告 本公告根據香港聯合交易所有限公司證券上市規則第13.09(2)條和第13.10B條及 香港法例第571章《證券及期貨條例》第XIVA部內幕消息條文作出。 下文為杭州泰格醫藥科技股份有限公司（「本公司」，連同其子公司統稱「本集團」） 2023年財政年度第一季度報告。本公告及隨附的財務報表最初以中文編製，並以 中英文版本刊登。如中英文版本有任何歧義或衝突，概以中文版本為準。 謹請本公司股東及公眾投資者注意，隨附財務報表乃根據中國企業會計準則編製 且未經審計。 承董事會命 杭州泰格醫藥科技股份有限公司 葉小平 董事長 ...

Financial Performance - Tigermed reported a total revenue of RMB 3.5 billion in 2022, representing a year-over-year growth of 25%[19]. - The company achieved a net profit of RMB 600 million, which is an increase of 30% compared to the previous year[19]. - The company's operating revenue for 2022 was CNY 7,085,471,468.87, representing a 35.91% increase compared to CNY 5,213,538,054.00 in 2021[27]. - The net profit attributable to shareholders decreased by 30.19% to CNY 2,006,552,035.30 in 2022 from CNY 2,874,163,020.17 in 2021[27]. - The net profit after deducting non-recurring gains and losses increased by 25.01% to CNY 1,539,519,788.35 in 2022[27]. - The total assets at the end of 2022 were CNY 27,446,510,596.44, a 15.61% increase from CNY 23,741,171,551.32 at the end of 2021[27]. - The basic earnings per share decreased by 29.91% to CNY 2.32 in 2022 from CNY 3.31 in 2021[27]. - The cash flow from operating activities for 2022 was CNY 1,357,500,892.41, a decrease of 4.66% from CNY 1,423,796,250.17 in 2021[27]. - The company's weighted average return on equity decreased to 10.72% in 2022 from 16.75% in 2021[27]. - The company reported a significant increase in financial assets, with total financial assets reaching ¥9,992,662,244.60, reflecting a growth in investment activities[107]. Strategic Focus and Growth - The report outlines the company's strategic focus on expanding its market presence and enhancing its service offerings through new technologies and products[8]. - The management discussion highlights the company's growth trajectory and future outlook, indicating a positive trend in revenue generation[8]. - Tigermed plans to expand its market presence in Southeast Asia, targeting a 20% increase in market share by 2024[19]. - The company is actively pursuing opportunities for mergers and acquisitions to bolster its competitive position in the market[8]. - The company aims to leverage its extensive network and partnerships to drive innovation in drug development and clinical trials[8]. - The company is investing RMB 200 million in new product development, focusing on digital health technologies[19]. - The company is exploring partnerships with biotech firms to enhance its service offerings and expand its portfolio[19]. - The company aims to continue selective acquisitions and investments for growth, but failure to identify suitable targets may hinder expected returns[127]. Compliance and Governance - The company emphasizes the importance of accurate and complete financial reporting, with all board members present for the report's approval[4]. - The company strictly adheres to legal and regulatory requirements for corporate governance, ensuring transparency and fairness in shareholder meetings[133]. - The company has established an audit committee to oversee internal and external audits, ensuring the authenticity and completeness of financial information[136]. - The company has maintained independence from its controlling shareholders in terms of operations, assets, and financial management[137]. - The company has a dedicated investor relations management system to enhance communication and transparency with investors[135]. - The company has implemented a business continuity plan to mitigate risks from unforeseen events, including natural disasters and pandemics[119]. Social Responsibility and Sustainability - The report details the company's commitment to social responsibility and environmental sustainability initiatives[8]. - The company received the highest AAA rating in the ESG rating from the Shenzhen Stock Exchange in July 2022[69]. - The company has implemented measures to reduce carbon emissions, although specific details were not provided[193]. - There were no administrative penalties due to environmental issues during the reporting period[193]. Employee and Management - The company has a total of 11 board meetings held during the reporting period, with all directors present at least once[157]. - The company’s total employee count increased from 8,326 to 9,233, reflecting growth in operational capacity[84]. - The company has implemented employee stock ownership plans and restricted stock incentive plans in 2017, 2019, 2020, and 2022 to retain talent[166]. - The company has conducted extensive employee training programs focusing on quality and compliance to enhance employee skills and organizational performance[167]. - The company is focused on maintaining a stable management team amidst personnel changes[143]. - The company has a strong management team with diverse backgrounds in pharmaceuticals, including ZHUAN YIN, who has unique experience in drug review, particularly in oncology[144]. Market Trends and Challenges - The global CRO market is projected to grow at a compound annual growth rate (CAGR) of 10.8%, reaching USD 126.99 billion by 2026[40]. - The clinical CRO market is expected to reach USD 78.04 billion by 2026, growing at a CAGR of 9.2%[40]. - The demand for reliable CRO services is increasing due to the complexity and high costs associated with new drug development, driving the need for integrated and innovative solutions[47]. - The company faces increasing competition from multinational CROs and domestic small and medium-sized CROs, which may lead to pricing pressure and reduced revenue and profitability[121]. - The company is facing uncertainties related to potential future disruptions that could adversely affect its business operations and financial performance[119]. - The demand for biopharmaceutical research and development services is at risk of decline due to potential slowdowns in the global pharmaceutical market and reduced outsourcing willingness from clients[120]. Financial Management and Investments - The company is actively pursuing new investment opportunities, including significant equity investments and ongoing non-equity investments[110]. - The company reported a net profit impact of ¥53,585,730 from fair value changes and ¥10,275,070 from investment income[99]. - The company has no current foreign currency hedging policy but will monitor foreign exchange risks and consider hedging when necessary[130]. - The company reported restricted assets totaling ¥54,194,256.65 in fixed deposits, indicating liquidity constraints[108]. - The company has established multiple subsidiaries, including Tigermed UK LTD and Tigermed Poland SP. Z O.O., with no significant impact on overall operations[118]. Clinical Research and Development - The company has developed a digital clinical trial platform, "Tailing Research," which includes various systems for clinical research management and risk-based quality management[48]. - The company launched the RBQM system (Phase II) in September 2022, focusing on data analysis and risk visualization for centralized monitoring[49]. - The company established a Decentralized Clinical Trial (DCT) department in early 2023 to develop and implement remote and intelligent clinical trial services[49]. - The company has successfully assisted in the approval of 4 COVID-19 vaccine products for emergency use in China and overseas during the reporting period[63]. - The company has maintained a market-leading position in China's clinical CRO industry, providing professional services for 65% of the new drug approvals in China since 2004[63].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭 州 泰 格 醫 藥 科 技 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3347） 截至2022年12月31日止年度之 年度業績公告 財務摘要 截至12月31日止年度 2022年 2021年 變動(2) 人民幣百萬元 人民幣百萬元 經營業績 收入 7,085.5 5,213.5 35.9% 毛利 2,785.4 2,248.1 23.9% 本公司擁有人應佔淨利潤 2,016.1 2,879.1 (30.0)% 本公司擁有人應佔經調整淨利潤(1) 1,665.8 1,585.3 5.1% 盈利能力 毛利率 39.3% 43.1% (3.8)% 本公司擁有人應佔淨利潤率 28.5% 55.2% (26.7)% 本公司擁有人應佔經調整淨利潤率(1) 23.5% 30.4% (6.9)% ...

Financial Performance - Total revenue for Q3 2022 reached CNY 1,811,809,605.48, representing a year-on-year increase of 35.35%[4] - Net profit attributable to shareholders for Q3 2022 was CNY 412,654,717.12, a decrease of 21.56% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 420,730,911.64, an increase of 29.02% year-on-year[4] - The company's operating revenue increased by 59.23% year-on-year, reaching ¥5,406,018,843.59, primarily due to increased customer demand and new clinical trial project revenues related to COVID-19[10] - Total revenue for the period reached CNY 5,406,018,843.59, a significant increase from CNY 3,395,015,172.83 in the previous period, representing a growth of approximately 59%[24] - Net profit attributable to shareholders of the parent company is 1,604,658,753.47, compared to 1,781,050,132.72 in the previous period, reflecting a decline of about 9.9%[30] - Total comprehensive income for the current period is 2,122,816,682.93, slightly down from 2,152,521,703.42 in the previous period, indicating a decrease of approximately 1.4%[31] - Basic earnings per share for the current period is 1.86, down from 2.05 in the previous period, a decrease of about 9.3%[31] Assets and Liabilities - The total assets as of the end of the reporting period amounted to CNY 27,140,006,778.09, reflecting a year-on-year growth of 14.32%[4] - Total assets increased to CNY 27,140,006,778.09 from CNY 23,741,171,551.32, reflecting a growth of about 14%[22] - The total liabilities rose to CNY 4,945,848,302.81 from CNY 3,135,974,351.68, an increase of approximately 58%[22] - The total owner's equity amounted to CNY 22,194,158,475.28, up from CNY 20,605,197,199.64, reflecting an increase of about 7.7%[23] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 825,385,230.87, an increase of 13.31% compared to the previous year[4] - Cash flow from operating activities increased to 4,990,906,039.78 from 3,132,970,902.71, representing a growth of approximately 59.2%[33] - Cash flow from investing activities resulted in a net outflow of -2,410,641,100.18, compared to -2,261,400,080.39 in the previous period, indicating a larger outflow[38] - Cash flow from financing activities generated a net inflow of 793,767,270.67, compared to a net outflow of -146,289,027.23 in the previous period, showing a significant turnaround[38] Inventory and Receivables - Accounts receivable increased by 39.76% to CNY 9,685,880.73 due to the receipt of bank acceptance bills from customers[8] - Inventory surged by 475.76% to CNY 35,093,313.34, primarily due to the purchase of experimental materials[8] - The company's inventory significantly increased to CNY 35,093,313.34 from CNY 6,095,078.95, representing a growth of about 475%[18] Investments and Goodwill - Long-term equity investments rose by 134.28% to CNY 1,730,862,925.56, attributed to increased investments in joint ventures[8] - Long-term equity investments surged to CNY 1,730,862,925.56, up from CNY 738,799,229.15, marking an increase of approximately 134%[19] - Goodwill increased by 40.68% to CNY 2,502,676,842.64, mainly due to goodwill generated from newly acquired subsidiaries[8] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 45,457[13] - The top shareholder, Ye Xiaoping, holds 20.32% of the shares, totaling 177,239,541 shares[14] Other Financial Metrics - The weighted average return on net assets was 2.18%, down by 0.86% from the previous year[4] - The company's gross profit margin was impacted as operating costs increased by 79.13% to ¥3,237,445,384.18, driven by higher sales and third-party supplier costs[10] - The company reported a 203.43% increase in credit impairment losses, amounting to -¥18,423,588.03, due to increased provisions for bad debts on accounts receivable[10] - The company’s other comprehensive income showed a significant change, with a decrease of 169.85% to ¥108,968,679.69, primarily due to foreign currency translation differences[9] - The company’s financial expenses decreased by 32.28% to -¥118,911,951.41 from -¥175,590,189.04, mainly due to reduced interest expenses from short-term borrowings[50] Audit Status - The report for the third quarter has not been audited[40] - The company did not conduct an audit for the third quarter report[80]

Financial Performance - Revenue for the six months ended June 30, 2022, was RMB 3,594.2 million, representing a 74.8% increase from RMB 2,056.4 million in the same period of 2021[10]. - Gross profit for the same period was RMB 1,418.3 million, up 46.7% from RMB 966.9 million year-on-year[10]. - Net profit attributable to owners of the company decreased by 5.4% to RMB 1,192.0 million from RMB 1,259.9 million in the previous year[10]. - Adjusted net profit attributable to owners increased by 26.6% to RMB 876.5 million compared to RMB 692.1 million in the prior year[10]. - Gross margin for the period was 39.5%, down from 47.0% in the previous year, reflecting a decrease of 7.5%[10]. - Net profit margin attributable to owners was 33.2%, a decline of 28.1% from 61.3% in the same period last year[10]. - Basic earnings per share for the period was RMB 1.38, a decrease of 4.8% from RMB 1.45 in the previous year[10]. - Adjusted basic earnings per share increased by 26.3% to RMB 1.01 from RMB 0.80 year-on-year[10]. - The adjusted net profit margin for the period was 24.4%, down from 33.7% in the previous year[56]. - Basic adjusted earnings per share increased from RMB 0.80 to RMB 1.01[56]. Revenue Breakdown - Revenue from clinical trial technology services reached RMB 2,172.1 million, representing a year-on-year increase of 110.1%, while revenue from clinical trial-related services and laboratory services was RMB 1,422.1 million, up 39.0% year-on-year[13]. - Revenue generated in China grew by 51.3% to RMB 1,680.8 million, benefiting from the company's leading position in the clinical services market[21]. - Overseas revenue surged by 102.3% to RMB 1,913.4 million, driven by demand for multi-regional clinical trials related to COVID-19[21]. - The company’s clinical trial-related services and laboratory services revenue increased from RMB 1,022.8 million to RMB 1,422.1 million, reflecting a year-on-year growth of 39.0%[33]. Market Position and Growth - The company maintained a leading position in China's clinical services market with a market share of 12.5% in 2021, an increase of 4.1% from 2019[13]. - The number of ongoing single-region clinical trials increased from 132 to 149 between December 31, 2021, and June 30, 2022[15]. - The company has established partnerships with over 1,200 clinical trial centers certified by the National Medical Products Administration in China, creating one of the largest clinical trial center networks in the country[86]. - The company has a diverse and loyal customer base, including leading multinational and Chinese biopharmaceutical companies, contributing to its revenue growth[91]. Strategic Initiatives - The company is focusing on expanding its market presence and enhancing its product offerings through new technologies and strategic initiatives[10]. - Future outlook includes continued investment in research and development to drive growth and improve profitability[10]. - The company has formed strategic partnerships with 21 clinical trial excellence centers to explore leading clinical research management platforms[16]. - The company continues to invest in centralized service centers in China to support global operations and enhance service delivery[15]. Operational Developments - The company established 26 overseas subsidiaries across 53 countries, employing over 1,100 overseas staff as of June 30, 2022[15]. - The number of ongoing drug clinical research projects increased from 567 to 607, with 400 projects in China and 207 overseas as of June 30, 2022[26]. - The company has implemented business continuity plans and emergency strategies to address disruptions caused by the pandemic[18]. - The company has established a comprehensive pandemic operation guideline to mitigate the impact of COVID-19 on clinical trial progress[24]. Expenses and Financial Management - Sales and marketing expenses increased by 19.9% to RMB 80.0 million, attributed to an increase in the number of sales and marketing personnel and their compensation[46]. - Administrative expenses rose by 30.3% to RMB 321.4 million, driven by increased employee costs and amortization of intangible assets[47]. - Research and development expenses increased by 18.8% to RMB 110.5 million, due to a rise in the number of employees involved in R&D activities and their compensation[48]. - Financial costs increased by 292.4% from RMB 7.9 million to RMB 31.0 million, primarily due to bank loan interest expenses rising to RMB 19.4 million[50]. Investments and Acquisitions - The company completed the acquisition of 88.1% of Frontage Clinical for approximately USD 13,215,000, which will be consolidated into the group's financial statements[190]. - The company’s acquisition of Experimur LLC in January 2022 aimed to expand GLP-compliant toxicology and related non-clinical development services[33]. - The company plans to utilize its strong investment and financing platform to enhance its core competitiveness in the biopharmaceutical sector[84]. - The company is focused on expanding its laboratory service capabilities through acquisitions, enhancing its clinical trial capabilities for medical devices[92]. Employee and Talent Management - Employee count remained stable at 8,299, with overseas employees increasing from 1,026 to 1,151 during the reporting period[19]. - The company has established a stock incentive plan for key employees, allowing them to share in the business growth, which is crucial for talent retention[122]. - The company is committed to continuous training programs for employees to enhance skills and knowledge, ensuring a capable workforce to meet service demands[129]. - The management team is experienced, with many members having previously worked at leading biopharmaceutical companies, enhancing the company's ability to address client challenges in clinical development[90]. Regulatory and Compliance Risks - The company must obtain and maintain various regulatory approvals and licenses; failure to do so could severely disrupt operations and impact financial performance[116]. - Increased competition in the global pharmaceutical contract research market may lead to pricing pressure, potentially reducing revenue and profitability[113]. - The company faces risks related to adapting to regulatory and policy updates, which could adversely affect its business, financial condition, and operating performance if not managed effectively[113]. Shareholder Returns and Equity Management - The company declared dividends amounting to RMB 432,463 thousand during the period, consistent with its commitment to return value to shareholders[200]. - The company plans to repurchase shares with a total amount not less than RMB 250 million and not exceeding RMB 500 million, with a maximum repurchase price of RMB 120.00 per share[96]. - As of the report date, the company repurchased a total of 3,909,800 A-shares, accounting for 0.4481% of the total share capital, with a total transaction amount of approximately RMB 369.39 million[96].